DURHAM, N.C.----Inspire Pharmaceuticals, Inc. announced today the receipt of a $1.25 million milestone payment from its Asian dry eye partner, Santen Pharmaceutical Co., Ltd., related to the completion of Santen's Phase 3 testing of diquafosol tetrasodium, referred to as DE-089, for the treatment...
[read full story]